Pharvaris N.V.
Pharvaris N.V. (PHVS) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · PHVS · as of Mar 31, 2025
Ownership Breakdown
52
Institutional Holders
▼ 2 vs Q4
$705.54M
Total Inst. Value
▼ $150.28M vs Q4
69.88M
Shares Outstanding
freeFloat 42.04%
44.94M
13F Shares Held
▲ 294,899 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
PHVS largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
GENERAL ATLANTIC, L.P. pharmaceutical preparations | 7.53M | 13.81% | 13.81% | $118.24B | May 14, 2025 | — held |
FMR LLC pharmaceutical preparations | 5.40M | 9.90% | 9.90% | $84.71B | May 12, 2025 | — held |
FORESITE CAPITAL MANAGEMENT IV, LLC pharmaceutical preparations | 4.41M | 8.09% | 8.09% | $69.25B | May 15, 2025 | ▲ 12.7K |
VENBIO PARTNERS LLC pharmaceutical preparations | 4.29M | 7.87% | 7.87% | $67.34B | May 15, 2025 | — held |
VIKING GLOBAL INVESTORS LP pharmaceutical preparations | 3.65M | 6.70% | 6.70% | $57.36B | May 15, 2025 | — held |
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC pharmaceutical preparations | 3.30M | 6.06% | 6.06% | $51.86B | May 15, 2025 | — held |
VR ADVISER, LLC pharmaceutical preparations | 3.11M | 5.71% | 5.71% | $48.87B | May 15, 2025 | ▼ 107.4K |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) pharmaceutical preparations | 2.02M | 3.70% | 3.70% | $31.67B | May 15, 2025 | — held |
COMMODORE CAPITAL LP pharmaceutical preparations | 1.91M | 3.51% | 3.51% | $30.01B | May 15, 2025 | — held |
NOVO HOLDINGS A/S pharmaceutical preparations | 1.73M | 3.16% | 3.16% | $27.08B | May 15, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
15
Increased
+369.3K shares3
New Positions
first time holders12
Decreased
−288.9K shares0
Sold Out
fully exitedNet shares change (top 50)
+80.4K
+369.3K / −288.9K
Net new holders
+6
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
PHVS insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Monges Viviane director | May 21, 2026 | Sale | 9,667 | $30.29 | $292.9K | 5.5K | Form 4 ↗ |
Nijdam Anna Principal Accounting Officer | May 22, 2026 | Sale | 5,501 | $30.74 | $169.1K | 48.9K | Form 4 ↗ |
Nijdam Anna Principal Accounting Officer | May 21, 2026 | Sale | 1,829 | $30.60 | $56.0K | 48.9K | Form 4 ↗ |
Nassif David W. CFO / CLO | May 21, 2026 | Sale | 10,000 | $30.31 | $303.1K | 120.3K | Form 4 ↗ |
Bjork Elisabeth director | May 20, 2026 | Sale | 10,000 | $29.32 | $293.2K | 15.2K | Form 4 ↗ |
Modig Berndt Chief Executive Officer | May 18, 2026 | Sale | 2,292 | $29.22 | $67.0K | 137.5K | Form 4 ↗ |
Glassman Robert director | May 15, 2026 | Sale | 5,333 | $29.83 | $159.1K | 15.2K | Form 4 ↗ |
Glassman Robert director | May 15, 2026 | Sale | 4,667 | $29.82 | $139.2K | 10.5K | Form 4 ↗ |
Abele Stefan Andreas Chief Technical Ops Officer | May 15, 2026 | Sale | 8,748 | $29.82 | $260.9K | 35.2K | Form 4 ↗ |
Souverijns Wim Chief Commercial Officer | May 15, 2026 | Sale | 10,000 | $29.92 | $299.2K | 45.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Pharvaris N.V. (PHVS) is primarily owned by institutional investors, who hold approximately 64.3% of total shares outstanding. Company insiders own approximately 57.96%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Pharvaris N.V. is GENERAL ATLANTIC, L.P., holding approximately 7.53 million shares — equal to 13.81% of outstanding shares — as of March 31, 2025.
A total of 52 institutional investors currently hold PHVS stock, with a combined institutional value of approximately $705,543,785 as of the most recent 13F filing period.
Frequently asked questions
PHVS ownershipPharvaris N.V. (PHVS) is primarily owned by institutional investors, who hold approximately 64.3% of shares. The largest shareholder is GENERAL ATLANTIC, L.P. with a 13.81% stake. Company insiders hold 57.96%. Data sourced from SEC Form 13F as of March 31, 2025.